Newly patented test may be a landmark in breast cancer detection
Jul 25, 2011
One of the main areas of research into breast cancer revolves around how to most accurately and efficiently diagnose risk and the disease itself. In breast cancer breakthroughs news, a newly patented test may hold the key to better breast cancer detection.
Atossa Genetics, Inc., a private healthcare company based out of Seattle, announced on July 13 that it received a patent for its new biomarker test.
The test uses a sensitive detection reagent to examine carbohydrates found in nipple aspirate fluid. The initial clinical trial of the test was successful, accurately coming up positive in all 12 of 28 tested women who have cancer. The test was negative in 12 out of the 16 women who don't have cancer.
The Chairman and CEO of Atossa Genetics, Dr. Steven C. Quay, announced, "It is known that some breast cancers contain alterations in the synthesis of cell surface and secreted glycoproteins and this test is designed to provide a sensitive signal of their presence in nipple aspirate fluid."
According to the National Cancer Institute, some breast cancer cases originally develop in the cells that line the inside of the breast's milk ducts. The biomarker test of Atossa Genetics may confirm the accuracy of using aspirate fluid as an indicator.